Cemiplimab with platinum-based chemotherapy (chemo) for first-line (1L) locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 3 subgroup analysis

In EMPOWER-Lung 3 (NCT03409614), a double-blind randomised phase 3 study of patients (pts) with advanced squamous or non-squamous NSCLC without EGFR, ALK or ROS aberrations, 1L cemiplimab + chemo demonstrated improved overall survival (OS) versus chemo alone (hazard ratio [HR] 0.71, P=0.014), a safety profile consistent with those previously reported for cemiplimab and chemo, and a favourable pt-reported outcome (PRO). Here, we report a post hoc subgroup analysis of pts with laNSCLC (Stage IIIb/c) who are not candidates for definitive concurrent chemoradiotherapy.